DGAP-News: Elanix Biotechnologies AG

PRESS RELEASE

Elanix Co-Founder Professor Wassim Raffoul Promotes State of the Art Burns, Plastic and Reconstructive Surgery Center Concept Incorporating Use of Progenitor Cell Services in Abu Dhabi Hospital

Elanix Cell Services Business Unit Provides State of the Art Burn, Plastic and Reconstructive Surgery Centers with Progenitor Cell Therapies to Accelerate Patients' Recovery

Nyon, Switzerland and Berlin, Germany, November 6, 2017 -- Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products and specialty cosmetics in dermatology and gynecology, announced today that co-founder, Professor Wassim Raffoul and his team at Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois, CHUV) aim to establish a strategic collaboration with the Abu Dhabi Health Services Company, SEHA, in the fields of burns, plastic and reconstructive surgery, rehabilitation and trauma. As part of the collaboration, the parties will establish the use of the progenitor cells and their derivatives at a state-of-the-art burn centre unit located in Sheikh Shakhbout Medical City, a leading medical facility providing superior healthcare services for the community, due to be opened in Q1 2018.

"Professor Wassim Raffoul is a leading advocate of the use of progenitor cell technologies in the treatment of acute and chronic wounds. His team at CHUV is actively using our "FirstCover" biological dressing concept product under the compassionate use program established more than 12 years ago," said Tomas Svoboda, CEO of Elanix. "Our expansive progenitor cell banks enable Elanix to offer Cells as a Service to provide a continuous supply of products based on progenitor cells and their derivatives to customers, such as hospital burns units, as well as for drug and cosmetic industry's development purposes."

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Elanix has its registered office in Berlin, Germany, with an office in Wiesbaden, Germany, and operational headquarters in Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com.

Press Contacts:

Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.